Cagrilintide is a long-acting amylin analogue studied in receptor pharmacology and human weight-management trials, both alone and alongside semaglutide.
Explore the research profileThe 5 mg quantity is provisional and awaits confirmation.
Submit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Amylin and calcitonin receptor agonist
Cagrilintide, also called AM833, is a lipid-modified peptide analogue of amylin, a pancreatic hormone involved in meal-related signaling. Its pharmacology differs from that of GLP-1 receptor agonists, even when the molecules are investigated together in the same clinical program.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Amylin receptors comprise a calcitonin receptor associated with receptor activity-modifying proteins. Cell studies characterize cagrilintide as an agonist at amylin receptors and the calcitonin receptor, with a distinctive pattern of binding and signaling. This receptor-family activity provides a mechanistic basis for investigating appetite and body-weight regulation.
Laboratory comparisons assessed cagrilintide against several related peptide agonists across receptor-binding and signaling measurements. The results caution against treating every amylin analogue as pharmacologically identical or assuming that one assay predicts all organism-level effects. [1]
A multicenter phase 2 trial studied cagrilintide alone in adults with overweight or obesity without diabetes. Weight reductions and tolerability were assessed against placebo and an active comparator. This is direct human evidence, although it remains specific to the studied formulation and population. [2]
The phase 3 REDEFINE 1 trial compared combined cagrilintide and semaglutide with individual components and placebo. It found substantial weight reduction with the combination. Combination results should not be attributed to cagrilintide alone or to unstudied mixtures. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Clinical evidence includes both single-agent and combination investigations. These answer different questions: whether cagrilintide has activity by itself, and whether combining distinct signaling pathways changes outcomes. Gastrointestinal adverse events were relevant to the clinical evaluation alongside weight-related endpoints.
Trial populations, comparators, follow-up and analysis assumptions influence estimated effects. Weight change does not by itself demonstrate benefit for every obesity-associated condition. CagriSema findings concern defined clinical products and cannot establish the effectiveness, safety or equivalence of WYZ research materials or independently assembled combinations.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Comparative amylin/calcitonin receptor pharmacology.
Randomized monotherapy phase 2 study; title abbreviated.
REDEFINE 1 combination study with component and placebo arms.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
